NeuroQuant® MS performance evaluation

Quantitative measurements of lesion volume and lesion distribution have significant value for clinicians evaluating disease progression. Subjective measurements based on a clinician’s visual inspection and manual lesion segmentation are often vulnerable to inter-and intra-rater variability, resulting in low reproducibility. Thus, objective, automated lesion segmentation tools have been developed [1-3] to overcome these problems. Since the appearance of lesions may vary across different MRI protocols, incorporating multiple MRI studies provides more information to accurately delineate lesions.


More Resources

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network

07/08/2026

The Hidden Tax on Every Head CT You Read

Why automated, consistent alignment, and the reformats it makes possible, may be the most overlooked upgrade in neuroimaging.

06/23/2026

Helping Our Clients Share Their Success Stories

Learn how Cortechs helps clients share clinical achievements, workflow improvements, and innovation through case studies, testimonials, webinars, and more.
Scroll to Top